Mitchell P. Levesque
YOU?
Author Swipe
View article: Suppl.Figure S16 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Suppl.Figure S16 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma Open
S16: scRNA-sequencing analysis of xenograft tumors M130227
View article: Suppl. Figure S12 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Suppl. Figure S12 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma Open
S12: Analysis of CyTof data from fresh melanoma tissue
View article: Table ST8 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Table ST8 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma Open
Table ST8: Data output of the CCLE cell line screening provided by Prof. Schreiber at Broad Institute.
View article: Table ST1 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Table ST1 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma Open
Table ST1: Summary of growth inhibitory IC50 values (including the corresponding 95% confident intervals (C.I.95%) conducted for neocuproine or MEKi (binimetinib) and primary human cell lines. The table includes the confirmed oncogenic mut…
View article: Suppl. Figure S7 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Suppl. Figure S7 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma Open
S7: Pathway enrichment (metabolomics)
View article: Suppl. Figure S10 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Suppl. Figure S10 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma Open
S10: Clinical data of orthologic slice cultures
View article: Suppl. Figure S13 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Suppl. Figure S13 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma Open
S13: Immunohistochemical analysis of CyTof biomarker panel.
View article: Suppl. Figure S6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Suppl. Figure S6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma Open
S6: Correlation analysis between MEKi and ROS.
View article: Suppl. Figure S14 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Suppl. Figure S14 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma Open
S14: CCLE cancer cell panel analysis for the responses to neocuproine
View article: Suppl Figure S4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Suppl Figure S4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma Open
S4: Neocuproine is a copper-dependent ROS inducer
View article: Supplementary Data from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Supplementary Data from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma Open
Tumor Profiler Consortium author list
View article: Table ST6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Table ST6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma Open
Table ST6: Differential expressed lipids and their FDRs in sensitive vs resistant cells (negative values are upregulated in sensitive cells).
View article: Suppl. Figure S5 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Suppl. Figure S5 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma Open
S5: Elevated cytoplasmic ROS induces apoptosis after the treatment with neocuproine
View article: Suppl. Figure S2 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Suppl. Figure S2 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma Open
S2: HPLC analysis of STO13881 and nNeocuproine showed overlapping profiles and confirmed STO13881 to be neocuproine (purchased from Sigma-Aldrich, Switzerland). High-performance liquid chromatography (HPLC) analysis was performed using the…
View article: Table ST5 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Table ST5 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma Open
Table ST5: Table of the 15 most informative proteins upregulated in MEK inhibitor-resistant cell culture (ranked by log2 fold-change).
View article: Suppl. Figure S3 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Suppl. Figure S3 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma Open
S3: Correlation between MEKi responsiveness and sensitivity to nNeocuproine
View article: Suppl. Figure S15 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Suppl. Figure S15 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma Open
S15: Tumor response curves in mice for ionophoric copper-chelators in combination with binimetinib.
View article: Table ST3 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Table ST3 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma Open
Table ST3: Differential expressed RNA transcripts between MEKi-sensitive and -resistant melanoma cell cultures.
View article: Combination of the Novel <scp>RAF</scp> Dimer Inhibitor Brimarafenib With the <scp>MEK</scp> Inhibitor Mirdametinib Is Effective Against <scp>NRAS</scp> Mutant Melanoma
Combination of the Novel <span>RAF</span> Dimer Inhibitor Brimarafenib With the <span>MEK</span> Inhibitor Mirdametinib Is Effective Against <span>NRAS</span> Mutant Melanoma Open
Metastatic melanoma, the most aggressive form of skin cancer, accounts for the majority of skin cancer‐related deaths. While targeted kinase inhibitors have improved outcomes for patients with BRAF‐mutated melanomas, their efficacy is ofte…
View article: B cell extracellular vesicles influence melanoma response to immune checkpoint therapy
B cell extracellular vesicles influence melanoma response to immune checkpoint therapy Open
The immune tumor microenvironment is a dynamic ecosystem where B cells play critical roles in modulating immune checkpoint blockade (ICB) therapy responses. While traditionally seen as passive players in tumor immunity, recent evidence sug…
View article: Transcriptomics- and 3D imaging–based characterization of the lymphatic vasculature in human skin
Transcriptomics- and 3D imaging–based characterization of the lymphatic vasculature in human skin Open
Afferent lymphatic vessels (LVs) are present in most vascularized tissues and exert important immune and drainage functions, yet human afferent LVs remain poorly studied. Performing single-cell RNA sequencing of lymphatic endothelial cells…
View article: p62 mRNA suppresses NLRP1 expression in cutaneous SCC cells through miR-34a-5p
p62 mRNA suppresses NLRP1 expression in cutaneous SCC cells through miR-34a-5p Open
The inflammasome sensor NLRP1 is mainly expressed by epithelial cells including keratinocytes of human skin. Germline gain-of-function mutations in NLRP1 cause inflammatory skin syndromes and predispose patients to the development of cutan…
View article: Immune-Related Cutaneous Adverse Events Display Distinct Clinical and Molecular Characteristics, Depending on Immune Checkpoints Targeted
Immune-Related Cutaneous Adverse Events Display Distinct Clinical and Molecular Characteristics, Depending on Immune Checkpoints Targeted Open
Background/Objectives: Immune-related cutaneous adverse events (ircAEs) are common complications of cancer immunotherapy and provide insight into immune-related adverse events (irAEs) more broadly. To enhance our molecular understanding, w…
View article: Protocol for analysis of miRNAs in human melanoma cells
Protocol for analysis of miRNAs in human melanoma cells Open
View article: Feasibility of multiomics tumor profiling for guiding treatment of melanoma
Feasibility of multiomics tumor profiling for guiding treatment of melanoma Open
There is limited evidence supporting the feasibility of using omics and functional technologies to inform treatment decisions. Here we present results from a cohort of 116 melanoma patients in the prospective, multicentric observational Tu…
View article: Standardization of Suspension and Imaging Mass Cytometry Single‐Cell Readouts for Clinical Decision Making
Standardization of Suspension and Imaging Mass Cytometry Single‐Cell Readouts for Clinical Decision Making Open
Suspension and imaging mass cytometry are single‐cell, proteomic‐based methods used to characterize tissue composition and structure. Data assessing the consistency of these methods over an extended period of time are still sparse and are …
View article: Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T cells in uveal melanoma patients
Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T cells in uveal melanoma patients Open
BACKGROUNDTebentafusp is the first T cell receptor-based bispecific protein approved for clinical use in HLA-A*02:01+ adult patients with unresectable/metastatic uveal melanoma. It redirects T cells toward gp100-expressing target cells, fr…
View article: A Retrospective Analysis of Ambiguous Spitz Tumors Using Next-Generation Sequencing
A Retrospective Analysis of Ambiguous Spitz Tumors Using Next-Generation Sequencing Open
Background: Spitz tumors (STs) are a diverse group of melanocytic lesions that range from benign to malignant. STs pose significant classification challenges due to overlapping histological and immunohistochemical (IHC) features among the …
View article: Topical Administration of Vitamin D2 Combined with Colloidal Silver Nanoparticles Promotes Wound Repair and Protection Against Skin Irritation and UVB Irradiation in 3D Reconstructed Human Skin Models
Topical Administration of Vitamin D2 Combined with Colloidal Silver Nanoparticles Promotes Wound Repair and Protection Against Skin Irritation and UVB Irradiation in 3D Reconstructed Human Skin Models Open
Background/Objectives: There is a great demand for novel, multipurpose, natural skin-care products in the global skin repair and sun protection markets. Within this framework, the potential benefits of topical Vitamin D2 (VD2) administrati…
View article: Supplementary Table 3 from Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma
Supplementary Table 3 from Temporal Genomic Analysis of Homogeneous Tumor Models Reveals Key Regulators of Immune Evasion in Melanoma Open
Pathway enrichment in samples at day 0 post-inoculation.